Diseases, Conditions, Syndromes

Tuberculosis—Inhibiting host cell death with immunotherapy

Tuberculosis treatment still entails the administration of several antibiotics over a period of months and is torturous for many patients. The pathogen's increasing multidrug resistance additionally complicates this lengthy ...

Cancer

Molecular mechanisms behind AICAr drug; impact on ALL

AICAr (5-amino-4-imidazolecarboxamide riboside, also called Acadesine) has been found to inhibit cell proliferation and has cytotoxic potential for childhood acute lymphoblastic leukemia (ALL) cells. Much of the drug's cytotoxic ...

Medical research

Compound identified that improves heart function in rats

Heart attack survivors may think the worst is behind them. But many later develop heart failure, a progressive disease marked by shortness of breath and swelling in the legs. Symptoms can prevent patients from working, exercising—even ...

Cancer

Melanoma: dabrafenib and trametinib have added benefit

The German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether the drug combinations of dabrafenib plus trametinib and of encorafenib plus binimetinib have an added benefit in comparison with ...

Cancer

New drug combination could be more effective against melanoma

A class of cancer drugs called protein kinase inhibitors is one of the most effective treatments for melanoma. However, in many cases, tumors eventually become resistant to the drugs and cause a relapse in the patient.

page 1 from 23

Kinase

In chemistry and biochemistry, a kinase is a type of enzyme that transfers phosphate groups from high-energy donor molecules, such as ATP, to specific substrates, a process referred to as phosphorylation. Kinases are part of the larger family of phosphotransferases. Kinases are not to be confused with phosphorylases, which carry out phosphorolysis, the breaking of a bond using an inorganic phosphate group; or with phosphatases, which remove phosphate groups.

This text uses material from Wikipedia, licensed under CC BY-SA